April 13, 2016 6:06pm

 

Appreciation has a “period” of being thankful but, I am not one to wait for the overbought bullet …

 

Do you care what happened today, you should because it has implications to tomorrow’s sector activity?   

Subscribe:  http://www.regmedinvestors.com/create-account   

 

Pre-open indication analysis – 1 hit and 3 misses

 

 

 

There is one thing that everyone needs, and that's interpretation and translation of intelligence, not just news or information - we get too much!

  • To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy regenerative medicine portfolio to track and monitor its pricing metric;

The takeaway is that investor need to decide what actions to take, or not take, based on their specific situation.

 

 

U.S. stocks closed 1% higher. The Dow closed up +1.06% higher at its highest level since Nov. 6. The S&P 500 closed up +1% and NASDAQ closed up +1.55% also closing at their highest levels of the year so far.

The NASDAQ closed UP +75.33 or +1.55% to 4,947.42 and the DOW closed UP +187.03 or +1.06% to 17,908.28.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.

  • Wednesday, the stem, cell and gene therapy and regenerative medicine sector opened positive with an A/DL of 26/12 and 5 flats;
  • The mid-day stayed positive with an A/DL of 30/10 with 3 flats;
  • The closing bell rang negative with A/DL of 34/9 with 0 flats

 

 

Henry’omics:

After a positive open, mid-day and close, the stem, cell and gene therapy and regenerative medicine felt the love of traders and momentum.

  • During these last three (3) months, the SCGT&RM sector have been stuck in the mud! The battle of the oversold and the overbought broke out with new highs and a catalyst for the oversold.

After Q1/16 unfolded, we saw that on the whole financial results/earnings were weak and have a potential to get weaker.

  • News is evidence of why a sector should appreciate and those don’t exist; so we are at the mercy of trading for explosive share pricing growth!

I am a “facts in evidence” guy and who needs the pages to turn on these momentum movers as sentiment still hovers to the downside!

  • For subscribers, I have been pushing a simple investment idea: trade … hold a lot of cash and wait to invest on follow-on corrections.

Looking and reviewing my pre-open post – this am … I was dead wrong but, I not perfect and have been early on a number of calls – I just don’t trust a trading market, it’s based on the nodes of a programs and  trader’s whim and fancy!

  • It is also counter to most of what I read in the financial media.

Both things make me more than sure that the right approach is to take your profit, even if you have to exhibit a bitter taste – there are no heroes in this market!

  • Patience is a virtue but, never run after a trade. There will always be another one.

 

 

Wednesday’s handicapping the sector pre-open indications – 1 hit and 3 misses

  • Applied Genetic Technologies (AGTC) closed UP +$1.05 – miss;
  • Juno Therapeutics (JUNO) closed UP +$1.13 – miss;
  •  MiMedx (MDXG) closed UP +$0.01 – hit;
  • Spark Therapeutics (ONCE) closed UP +$1.98 – miss;

 

 

Out and about:

Intrexon (XON) closed UP +2.70 to $35.69 after being down --$0.18 in a yesterday’s range of $32.08 to $33.83.

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Wednesday traded below 14;
  • Tuesday traded near 15;
  • Monday traded above 16;
  • Friday traded near 15.4 – down!
  • Thursday traded near 16.7;
  • Last, Wednesday traded below 14.5;

 

 

Riding the indexes and ETFs roller-coaster:

  • The iShares Biotechnology Stocks ETF (IBB) closed UP on Wednesday +5.28 or +1.91%
  • The NASDAQ Biotechnology index (NBI) closed UP +55.80 or +1.93%
  • The Russell 2000 (IWM) closed UP +2.37 or +2.16%
  • The SPDR SD&P Biotech ETF (XBI) closed UP +1.33 or +2.42%

 

 

Who was leading the declines – to of the bottom 5?

  • uniQure (QURE) closed down -40.32 to $12.79;
  • Regenxbio (RGNX) -$0.11 to $11.42;
  • ReNeuron (RENE.L) -$0.10 to $2.90;
  • Biostage (BSTG) -$0.05 to $1.83;
  • International Stem Cell (ISTO) closed down -$0.03 to $4.01

 

 

Who was UP – top 5:

  • Bluebird bio (BLUE) closed up +$3.07 to $50.73;
  • Intrexon (XON) +$2.07 to $35.69;
  • Spark therapeutics (ONCE) +$1.98 to $35.10;
  • Cellectis SA (CLLS) +$1.19 to $28.78;
  • Juno Therapeutics (JUNO) closed up +$1.13 to $43.09;

 

 

Most active sector stocks + and -:

  • ImmunoCellular (NYSEMKT: IMUC) -3.48%;
  • ReNeuron (RENE.L) -3.33%;
  • Biostage (BSTG) -2.66%;

Versus …

  • Athersys (ATHX) +12.86%;
  • Pluristem (PSTI) +12.42%
  • Osiris (OSIR) +9.15%;

 

 

Who was FLAT?

0

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.